Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abetted, add, admit, affirming, andAzaSitefor, andProlacriaTM, antibioticsVigamox, Apotex, areProlacria, asZylet®by, audience, Australia, AzaSitein, besifloxacin, bothProlacriaand, burdensome, capacity, categorized, cited, clause, commonly, constriction, coveringElestatin, crossed, dealer, deny, Dermatologic, desist, dispensed, Dr, ElestatPatent, entrance, evidenced, exit, filer, flexibility, fold, forAzaSiteandElestat, forAzaSitefor, forBepreve, forElestatduring, forElestatunder, forProlacriawill, frequency, fromAzaSite, gathered, hierarchy, hypertension, inconclusive, instability, Investor, IOP, IV, Japanese, Likewise, mannitol, milliliter, Ministry, Moody, NEI, netAzaSite, nonrecurring, Notwithstanding, ofAzaSiteandElestat, ofElestator, ofProlacriain, ofProlacriaunder, ofRestasisat, orderly, overallProlacriaclinical, Paddock, paper, Poor, powder, preliminary, Presidential, promotingAzaSiteand, quoted, refocused, regardingProlacria, Sandoz, slightly, SPA, strength, studyAzaSitefor, subprime, supportAzaSiteandElestat, surrogate, theElestatPatent, toAzaSiteand, toProlacria, toProlacriaor, toRestasisand, toRestasismay, unadjusted, unchanged, unenforceable, unobservable, unstable, upfrontAzaSite, warning, Welfare, whichAzaSite, whichElestat, withAzaSiteevaluating, withAzaSiteinclude, worsen, Zealand
Removed:
achieving, added, adulterated, aggressive, aggressively, AlthoughZithromax, announcement, antagonist, antiplatelet, APB, AQ, Aqua, attractive, augment, biological, certainty, chronic, committed, Complement, consolidation, contemplated, contractually, coordinate, core, counsel, DC, deceptive, defendant, deterioration, digestive, digit, directed, discovering, diversion, Dutch, dysfunction, efficiently, effort, element, encompassed, energy, enhancing, enjoin, enrich, eventual, executed, expectancy, expedited, fast, favorably, focusing, forma, formal, freely, healthcare, histamine, hydrated, improperly, infrastructure, infringing, inhibitor, invalidation, invariably, involving, leading, line, liquid, liquidate, lot, median, metabolic, Military, misbranded, mortality, mutation, ninety, nonpublic, objective, officially, opportunistic, optimize, OTC, outlining, Overview, penetration, perfecting, perpetual, pharmacologically, poorly, prescribing, prevailing, principle, pro, proceeding, professional, prohibition, projection, promote, properly, purported, reclassified, recognizing, regimen, regulator, remedy, reset, retaining, ringo, school, Seizing, select, situation, sooner, spent, stability, suffering, sum, surveillance, suspending, switch, synthesize, synthetic, Terrorist, top, track, tradable, trading, transition, translational, transmembrane, unforeseen, unrest, unspecified, vigorously, violative, voluntarily, Weather, william, Withdrawing, yielding
Filing tables
Filing exhibits
- 10-K Annual report
- 10.62 Second Amendment to License, Development and Marketing Agreement
- 10.63 Amended and Restated Director Compensation Policy
- 23.1 Consent of Pricewaterhousecoopers LLP, Independent Registered Public Accounting.
- 31.1 Section 302 CEO Certification
- 31.2 Section 302 CFO Certification
- 32.1 Section 906 CEO Certification
- 32.2 Section 906 CFO Certification
Related press release
ISPH similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-147733 and 333-141169) and Form S-8 (Nos. 333-56360, 333-130496 and 333-148185) of Inspire Pharmaceuticals, Inc. of our report dated March 13, 2009 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Raleigh, North Carolina
March 13, 2009